Gene Therapy Clinical Trial Webpage

What is gene therapy?

Gene therapy can be defined as the introduction of genetic material to cells of individuals for therapeutic benefit. In simple terms, it involves providing a healthy functional copy of a gene to the patient’s cells to compensate for a defective copy that causes the disease. Ideally this treatment would only need to be administered once in the lifetime of the patient. Even though the concept
underlying gene therapy is straightforward, delivering genes into cells of a living organism is a very challenging process. Therefore, an essential component of gene therapy studies is the development of vectors that can efficiently deliver genetic material into cells.

For Type 1 Gaucher disease, there are a number of gene therapy clinical trials currently looking for participants to take part in. We have compiled information about these trials below with the aim of making it easy for the community to understand the similarities and differences between them.

There are multiple factors to consider when deciding whether or not to take part in any form of medical research. Please note that each clinical trial is unique and the intention of capturing the information below is not to suggest that any trial is preferable to another.

If you or a loved one are interested in taking part in a clinical trial, please speak to your doctor about the options available to you.

Overview of clinical trials using gene therapy for the treatment of Type 1 Gaucher disease

 

 

 

 


Details

Company 

 

Study name

PROCEED

GALILEO-1

Guard1

Usually, trials have specific names to make them easier
to remember

ID number

NCT05487599

NCT05324943

NCT04145037

The ID code connects to a clinicaltrial.gov page capturing all
trial information

Status

Recruiting

Recruiting

 

Stopped

(due to
a business decision not to proceed, and not due to any safety or efficacy
issue)

 

Study phase

1/2

1/2

1/2

The phase explains how far an experimental medicine is in its
research. Phase 1 usually looks at safety and how the body processes the
medicine, while phase 2 explores what dose of medicine is best and if it
works well enough to be studied in a larger trial

Aim of the study

As all three studies are
in the same research phase, their aim is similar in nature: to see if their
experimental medicine works in people with Type 1 Gaucher disease, and to
understand how safe and tolerable it is among the participants. Some studies
may also look at other, secondary effects.

 

Gene Therapy
being studied

LY3884961

FLT201

AVR-RD-02

Each company will have given their experimental medicine a name
to refer back to in all research

Other medicines given during the study?

Methylprednisolone

Sirolimus

Prednisone

Unknown

 

Any
medicines given in addition to FLT201 will be done as the discretion of your treatment
team..

Busulfan

 

It is possible
other medicines will be given during the study.

It is not unusual for other medicines to be given
alongside the main treatment

Study locations

(see map below)

US-based study, looking to enroll approx. 15
participants

Global study, looking to enroll approx. 18
participants spanning the US, Europe, Middle East
and South America

US and Canada-based study, which has enrolled 7
participants

 

Length of study

(incl. screening)

For those taking part,
it is expected the study can take up to approx. 5 years

For those taking part,
it is expected the study can take up to approx. 1 year (54 weeks)

For those taking part,
it is expected the study can take up to approx. 70 weeks

 

Number of visits

4 visits in the first two months, then one visit
per quarter in the first year. In year 2, one visit
every 6 months,

then once per year for 3 years

Unknown

 

The number of visits will be confirmed with your treatment team. All people who have received the
therapy will be followed for at least 5 years following treatment.

Approximately 30 visits over the course of the
study

 

Costs of participation covered?

 

 

 

 

Any travel
for the study, including internationally, are
provided at no cost to you.

 

 

Key criteria to take part (inclusion criteria)

18 – 65 years old

Have the bi-allelic GBA1 mutation

<![if !supportLists]>»
<![endif]>Been on ERT/SRT
treatment for at least 2 years
(stable, tolerated dose)

<![if !supportLists]>»
<![endif]>Not
responding well to ERT/SRT treatment

<![if !supportLists]>»
<![endif]>No
family planning during the study period

<![if !supportLists]>»
<![endif]>Refrain
from blood donations during the study period

18+ years old

Have the GBA1 mutation

<![if !supportLists]>»
<![endif]>Been on ERT/SRT
treatment for at least 2 years
(no change in regimen for 3 months prior to dosing)

<![if !supportLists]>»
<![endif]>No
family planning during the study period

 

18 – 50 years old (post puberty)

Have the GBA1 mutation

<![if !supportLists]>»
<![endif]>No
family planning during the study period
(egg retrieval and egg/sperm preservation is offered)

<![if !supportLists]>»
<![endif]>Refrain
from blood, organ, tissues, cell, egg, and sperm donations during the study
period

<![if !supportLists]>»
<![endif]>Willing
to receive blood transfusions

 

Open to both people with at least 2 years of stable ERT treatment
and those who have not received any ERT/SRT treatment. Put into two separate
groups for the study.

 

Key exclusion criteria

<![if !supportLists]>x
<![endif]>Significant neurological
signs and symptoms and/or behavioral difficulties

<![if !supportLists]>x
<![endif]>Received any type of gene or
cell therapy previously

<![if !supportLists]>x
<![endif]>Previous participation in
another clinical study

<![if !supportLists]>x
<![endif]>People on specific
medications or with specific conditions, which may mask results of the
experimental medicine or pose a risk for the participant

<![if !supportLists]>x
<![endif]>Those who are expecting a
baby

<![if !supportLists]>x
<![endif]>History of certain cancers within
5 years of participating

<![if !supportLists]>x
<![endif]>Evidence of enlarged spleen,
total removal of the spleen or advanced liver disease

<![if !supportLists]>x
<![endif]>Lower than normal blood
count

<![if !supportLists]>x
<![endif]>Severe neurological signs and symptoms or
Type 2 or 3 Gaucher disease

<![if !supportLists]>x
<![endif]>Received any type of gene
therapy previously

<![if !supportLists]>x
<![endif]>Participation in another clinical trial during
the study

<![if !supportLists]>x
<![endif]>People on specific
medications or with specific conditions, which may mask results of the
experimental medicine or pose a risk for the participant

<![if !supportLists]>x
<![endif]>History of substance abuse

<![if !supportLists]>x
<![endif]>History of neoplastic disease (tumor growth)

<![if !supportLists]>x
<![endif]>Presence of hepatitis B, C, HIV

<![if !supportLists]>x
<![endif]>Evidence of liver dysfunction or advanced
liver disease

<![if !supportLists]>x
<![endif]>Lower than normal blood count

<![if !supportLists]>x
<![endif]>Type 2 or 3 Gaucher disease, including eye
movement abnormality on clinical examination

<![if !supportLists]>x
<![endif]>Received any type of gene
therapy previously

<![if !supportLists]>x
<![endif]>Participation in another clinical trial during
the study

<![if !supportLists]>x
<![endif]>People on specific
medications or with specific conditions, which may mask results of the experimental
medicine or pose a risk for the participant

<![if !supportLists]>x
<![endif]>Those who are expecting a
baby

<![if !supportLists]>x
<![endif]>History of substance abuse

<![if !supportLists]>x
<![endif]>History of cancer

<![if !supportLists]>x
<![endif]>Presence of hepatitis B, C, HIV

<![if !supportLists]>x
<![endif]>Evidence of enlarged spleen

<![if !supportLists]>x
<![endif]>Lower than normal blood count

 

 

Each study will have additional inclusion and
exclusion requirements that must be met in order to
take part, which a doctor can advise on if you or a loved one is interested
in taking part.

 

What does the study look like?

This study is set up
as open label as there is no placebo (‘dummy treatment’) included,

so both the
physician and participant know that they are receiving the medicine being
investigated in the trial.

You may come across the terms ‘non-randomised
or ‘open label’, which mean the physician controls which participant goes
into what study group and everyone knows which treatment they are giving or
receiving.

Three study groups will be set up to investigate
three different doses of the treatment, with each participant being allocated
by the study physician.

A single participant group will be set up for this
study, so no allocation is needed.

Two study groups will be included, one for those
who have previously had ERT/SRT therapy and the other for those that have
not.

Delivery of treatment

Each participant will be given a single
dose of LY3884961 by IV infusion.

Each participant will be given a single
dose of FLT201by IV infusion.

Each participant will be given a single
dose of AVR-RD-02 by IV infusion.

 

 

Pre-screening & conditioning?

 

<![if !supportLists]>·
<![endif]>Written
consent

<![if !supportLists]>·
<![endif]>Screening
procedures

 

 

<![if !supportLists]>·
<![endif]>Written
consent

<![if !supportLists]>·
<![endif]>Screening
procedures

 

 

<![if !supportLists]>·
<![endif]>Written
consent

<![if !supportLists]>·
<![endif]>Screening
procedures

<![if !supportLists]>·
<![endif]>Baseline
assessments

<![if !supportLists]>·
<![endif]>Pre-infusion
period (8-10 weeks) when participants are prepared for gene therapy through
mobilization, apheresis, and conditioning. Mobilization helps the bone marrow
release stem cells into the bloodstream, where they can be collected and
selected by a process called apheresis.

Conditioning
prepares the body to receive gene therapy

 

 

 



 

Clinical trial sites

 

 

BLUE: Prevail Therapeutics | RED: Freeline Therapeutics | GREEN: AVROBIO

Further details of the
locations/hospitals can be found in by clicking the links above.

 

 

 

 

 

 

Note: Company logos are hyperlinks directing to the company’s website.
× How can I help you?